Windtree Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jed Latkin
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 4.5yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)
Dec 06Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions
Jul 06Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable
Jun 09
Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?
Feb 09CEO
Jed Latkin (50 yo)
less than a year
Tenure
Mr. Jed A. Latkin has been the Chief Executive Officer and President of Windtree Therapeutics Inc. since December 01, 2024. He serves as Chief Operating Officer & Head of Finance Department of ProPhase Lab...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Senior VP & COO | 4.8yrs | US$451.73k | 0.0095% $ 272.4 | |
| Senior VP & Chief Medical Officer | 10.3yrs | US$491.73k | 0.00067% $ 19.2 | |
| CEO, President & Director | less than a year | no data | no data | |
| Senior VP | 1.4yrs | no data | 0.0063% $ 181.3 | |
| Vice President of Technical Operations | no data | no data | no data | |
| Executive Director of Clinical Development | 4.5yrs | no data | no data | |
| Head of Operations & Program Management | 4.5yrs | no data | no data |
4.5yrs
Average Tenure
56yo
Average Age
Experienced Management: WINT's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | no data | no data | |
| Lead Independent Director | 1.6yrs | US$32.34k | no data | |
| Independent Director | less than a year | no data | no data | |
| Chairman | 8.9yrs | US$693.63k | 0.0066% $ 190.5 |
1.0yrs
Average Tenure
53.5yo
Average Age
Experienced Board: WINT's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 10:01 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Windtree Therapeutics, Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vernon Bernardino | H.C. Wainwright & Co. |
| Andrew Fein | H.C. Wainwright & Co. |
| John Tanner | Lazard Capital Markets |